Akebia Therapeutics Statistics
Share Statistics
Akebia Therapeutics has 218.18M shares outstanding. The number of shares has increased by 4.21% in one year.
| Shares Outstanding | 218.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.75% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 207.61M |
| Failed to Deliver (FTD) Shares | 4.14K |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 14.07M, so 6.45% of the outstanding shares have been sold short.
| Short Interest | 14.07M |
| Short % of Shares Out | 6.45% |
| Short % of Float | 6.78% |
| Short Ratio (days to cover) | 6.91 |
Valuation Ratios
The PE ratio is -4.48 and the forward PE ratio is -7.5.
| PE Ratio | -4.48 |
| Forward PE | -7.5 |
| PS Ratio | 1.19 |
| Forward PS | 1.7 |
| PB Ratio | -7.6 |
| P/FCF Ratio | -9.94 |
| PEG Ratio | n/a |
Enterprise Valuation
Akebia Therapeutics Inc. has an Enterprise Value (EV) of 293.71M.
| EV / Earnings | -5.66 |
| EV / Sales | 1.51 |
| EV / EBITDA | -42.77 |
| EV / EBIT | -6.35 |
| EV / FCF | -12.56 |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of -3.41.
| Current Ratio | 1.18 |
| Quick Ratio | 1.03 |
| Debt / Equity | -3.41 |
| Total Debt / Capitalization | 141.56 |
| Cash Flow / Debt | -0.22 |
| Interest Coverage | -7.67 |
Financial Efficiency
Return on equity (ROE) is 1.7% and return on capital (ROIC) is -62.85%.
| Return on Equity (ROE) | 1.7% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -62.85% |
| Revenue Per Employee | 1.17M |
| Profits Per Employee | -310.93K |
| Employee Count | 167 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 4.73 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 31.03% in the last 52 weeks. The beta is 0.73, so Akebia Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.73 |
| 52-Week Price Change | 31.03% |
| 50-Day Moving Average | 1.9 |
| 200-Day Moving Average | 1.46 |
| Relative Strength Index (RSI) | 51.91 |
| Average Volume (20 Days) | 2.23M |
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 194.62M and earned -51.92M in profits. Earnings per share was -0.28.
| Revenue | 194.62M |
| Gross Profit | 120.47M |
| Operating Income | -46.26M |
| Net Income | -51.92M |
| EBITDA | -6.87M |
| EBIT | -46.26M |
| Earnings Per Share (EPS) | -0.28 |
Balance Sheet
The company has 42.92M in cash and 104.18M in debt, giving a net cash position of -61.26M.
| Cash & Cash Equivalents | 42.92M |
| Total Debt | 104.18M |
| Net Cash | -61.26M |
| Retained Earnings | -1.61B |
| Total Assets | 207.14M |
| Working Capital | 34.41M |
Cash Flow
In the last 12 months, operating cash flow was -23.38M and capital expenditures 0, giving a free cash flow of -23.38M.
| Operating Cash Flow | -23.38M |
| Capital Expenditures | 0 |
| Free Cash Flow | -23.38M |
| FCF Per Share | -0.12 |
Margins
Gross margin is 61.9%, with operating and profit margins of -23.77% and -26.68%.
| Gross Margin | 61.9% |
| Operating Margin | -23.77% |
| Pretax Margin | -26.68% |
| Profit Margin | -26.68% |
| EBITDA Margin | -3.53% |
| EBIT Margin | -23.77% |
| FCF Margin | -12.02% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.74% |
| FCF Yield | -5.64% |
Analyst Forecast
The average price target for AKBA is $7.5, which is 294.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.5 |
| Price Target Difference | 294.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -9.73 |
| Piotroski F-Score | 5 |